Wild-type IDH1 inhibits the tumor growth through degrading HIF-α in renal cell carcinoma
Open Access
- 1 January 2021
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 17 (5) , 1250-1262
Abstract
The purpose of our study was to explore the effect and intrinsic mechanism of wild-type IDH1 and its substrate α-KG on renal cell carcinoma (RCC). IDH1 was observed lower expression in RCC cell lines. Phenotype experiment was carried out in the wild-type IDH1 and mutant IDH1R132H plasmid treated cell line. The results showed that the wild-type IDH1 could significantly inhibit the proliferation, migration and promote the apoptosis of RCC cell lines, which were consistent with the IDH1's substrate α-KG. The mutant IDH1R132H was found to lose this biological function of IDH1. Moreover, we verified the proliferation inhibition of IDH1 in vivo. In addition, we verified the correlation between IDH1 and hypoxia signal-related proteins in vitro and in vivo, specifically, IDH1 overexpression could significantly reduce the expression of HIF-1α and HIF-2α proteins and its downstream proteins (VEGF, TGF-α). Furthermore, we preliminarily verified the possibility of α-KG in the RCC's treatment by injecting α-KG into the xenograft model. α-KG significantly reduced tumor size and weight in tumor-bearing mice. This study provided a new therapeutic target and small molecule for the study of the treatment and mechanism of RCC.Keywords
This publication has 27 references indexed in Scilit:
- Integrated molecular analysis of clear-cell renal cell carcinomaNature Genetics, 2013
- Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Non–Muscle-Invasive Bladder CancerEuropean Urology, 2011
- IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1αScience, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal TumorsClinical Cancer Research, 2008
- Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase PathwayMolecular Cell, 2008
- Radical Cystectomy – Often Too Late? Yes, But …European Urology, 2006